Page last updated: 2024-12-08

2,5-dimethoxy-4-iodoamphetamine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID170617
CHEMBL ID1255748
SCHEMBL ID874013
MeSH IDM0065616

Synonyms (52)

Synonym
EU-0100466
(+/-)-doi hydrochloride, >=98% (hplc), solid
doi hydrochloride
benzeneethanamine, 4-iodo-2,5-dimethoxy-alpha-methyl-, hydrochloride
(+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride
(+/-)-doi hydrochloride
MLS000860069
smr000326927
2,5-dimethoxy-4-iodoamphetamine hydrochloride
NCGC00093879-01
(?)-doi hydrochloride
D-101 ,
( inverted question mark)-doi hydrochloride
( inverted question mark)-2,5-dimethoxy-4-iodoamphetamine hydrochloride
82830-44-2
1-(4-iodanyl-2,5-dimethoxy-phenyl)propan-2-amine hydrochloride
1-(4-iodo-2,5-dimethoxyphenyl)-2-propanamine hydrochloride
A840459
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine hydrochloride
CHEMBL1255748
MLS002320685
smr001338831
42203-78-1
unii-q2e57v2ws3
doi hcl
4-iodo-2,5-dimethoxyphenylisopropylamine, hydrochloride
doi cpd hydrochloride
q2e57v2ws3 ,
82864-02-6
LP00466
(+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride
SCHEMBL874013
4-iodo-2,5-dimethoxy-?-methylbenzeneethanamine hydrochloride
(+/-)-2,5-dimethoxy-4-iodoamphetamine hydrochloride
AKOS024457216
4-iodo-2,5-dimethoxyphenylisopropylamine hydrochloride
benzeneethanamine, 4-iodo-2,5-dimethoxy-.alpha.-methyl-, hydrochloride (1:1)
SR-01000075550-1
sr-01000075550
FT-0732038
FT-0728883
c11h16ino2.hcl
4-iodo-2,5-dimethoxy-alpha-methylbenzene ethanamine hydrochloride
(+/-)-doi hydrochloride (+-)-2,5-dimetho xy-4-
Q27286917
DTXSID50962366
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine--hydrogen chloride (1/1)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine;hydrochloride
r(-)-doi hydrochloride potent and select ive
doi (hydrochloride)
d,l-doi.hcl
d,l-doi.hcl, 1mg/ml in methanol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
endonuclease IVEscherichia coliPotency0.44670.707912.432431.6228AID1708
glp-1 receptor, partialHomo sapiens (human)Potency22.38720.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency18.35640.000811.382244.6684AID686978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency11.22020.035520.977089.1251AID504332
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency67.455523.934123.934123.9341AID1967
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency15.84890.01789.637444.6684AID588834
M-phase phosphoprotein 8Homo sapiens (human)Potency1.00000.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency0.00140.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]